REGENXBIO Faces Class Action Over Gene Therapy Safety Disclosures
REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.
RGNXsecurities fraudclass action lawsuit








